1logoneur085-Correction

 

We publish a newsletter which is sent to all members, doctors surgeries, libraries, national and local politicians. The newsletter includes details of our events together with news about advances in the treatment of epilepsy and changes in benefits available to members. To see the latest edition View here

 

The next meeting of Epilepsy HERE will be held  at Canterbury Umbrella Centre ,St Peter's Place, Canterbury,Kent,CT1 2DB on Tuesday 7th February 2017 at 7.30 pm  The speaker will be Dr. Trudy Thomas from the Mdway School of Pharmacy who has made a study of epilepsy medication and conducted hands end reviews of such drugs. We hope for a good attendance as it the first time we have heard from a phamacist on these issues.

There will be  no Coffee Break meeting at Whitstable United Reformed Church Middle Wall Whitstable  CT5 1BW in December the next meeting will be onon Tuesday 17th January 2017 from 10.00-11.30 a.m. Come along to meet us and chat

 

The sales of Christmas Cards will finish at Kent & Canterbury Hospital on Thursday 8th December 2016. We expect to hve raised about £760 for research this year.

GlaxoSmithKline (GSK) is advising Healthcare Providers that Trobalt® (retigabine) tablets (50mg, 100mg, 200mg, 300mg and 400mg) will no longer be commercially available after June 2017. GSK intends to discontinue the product permanently due to the very limited usage of the medicine and the continued decline in new patient initiation.
Therapeutic Indication: Trobalt® is indicated as adjunctive treatment of drug-resistant partial onset seizures with or without secondary generalization in patients aged 18 years or older with epilepsy, where other appropriate combinations with other medicinal products have proved inadequate or have not been tolerated.
Ke y Messages
• Trobalt® will be discontinued from all markets in June 2017 for commercial reasons.
• Healthcare Providers should therefore begin seeking alternative medicines for existing patients as soon as possible, and ensure that all patients are withdrawn from this medicine by the end of June 2017 at the latest.
• Patients’ treatment should be withdrawn with a gradual dose reduction over a period of at least 3 weeks, in accordance with the current prescribing information.
• All patients should continue to receive safety monitoring in line with the local prescribing information whilst they remain on treatment with Trobalt®.
• Given the planned product discontinuation, no new patients should now start treatment with Trobalt®.
Cutterguide: N/A Printing Process: Offset GD: RS 462682
Size: 210 x 297 mm Pages: 2 Colors: C M Y K (4 Colors) Native File: Indesign CC Windows Generated in: Acrobat Distiller 11.0
UK/RET/0091/16 August 2016
UK_RET_0091_16_GSKDC-PT-GBR-2016-10056_D2.indd 1 UK_RET_0091_16_GSKDC-PT-GBR-2016-10056_D2.indd 1 8/23/2016 9:05:12 PM 8/23/2016 9:05:12 PM
Action Being Taken by GlaxoSmithKline GSK is communicating this information to regulatory authorities and Healthcare Providers. GSK is working closely with our distributors to ensure the medicine remains available to existing patients for the next year, providing sufficient time for a treatment alternative to be identified and initiated, where appropriate.
Action required by Healthcare Providers In view of the planned discontinuation of this medicine, Healthcare Providers are advised to start seeking an alternative anti-epileptic drug as soon as possible to replace Trobalt® where necessary. All patients will need to have had their Trobalt® treatment discontinued by the end of June 2017 at the latest. Healthcare Providers should not initiate any new patients on Trobalt®.

DRUG alert Epistasus    

Drug alert number: EL (16)A/06

Date issued: 25th May 2016

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 patient level recall to be actioned within 48 hours, for a batch of:

Epistatus 10mg/ml oromucosal solution pack size 1 x 5ml (Special

 

 For the latest News from the International Alliance of Patients Associations (IAPO) click here

New Clinical Chair for Canterbury and Coastal CCG

Dr Sarah Philips from Newton Place Surgery in Faversham has replaced Dr Mark Jones as Clinical Chair of the Canterbury and Coastal CCG the body which commissions health services in Canterbury, Faversham and Sandwich area.

 

NHS in East Kent to combine 111 and out of hours care

The new service will combine 111 the emergency number, with out of hours service providing care fro patients who need to see a GP urgently when the practice they normally attend is closed. This will be further enhanced with a crae navigation service which will help patirnts with more complex needs to remain at home. Care navigation enables healthcare professionals look at the holistic needs of the patient. They will be enabled to  refer patients to different services such as a district nurse to dress wounds or an occupational therapist to carry out an equipment assessment. The CCG intend to award the contract to run the new integrated urgent care service to Primecare. .At present 11 can only refer callers to a single place. A new call centre will be located in East Kent to receive calls from East Kent.

Introducing a better quality transport service

A new and improved patient transport service is being launched across Kent and Medway on 1 July 2016. Tough new measures to raise standards are being introduced, with greater emphasis on customer care and getting patients home from hospital promptly.

The service, which is for people who cannot get to their NHS funded hospital or clinic appointment in any other way because of their medical or physical condition, is provided by G4S. The company is taking over from NSL whose contract expires on 30 June.

G4S’s performance will be measured against a Patient Charter, developed by people who use patient transport services in Kent and Medway. There are tighter timescale targets for picking up and dropping off patients, and for how long they spend in transit.

Patients have been involved in preparations for the start of the new service and in making it easier for the PTS eligibility criteria to be applied in a completely fair and consistent way.

The bookings line is a freephone number open 24 hours a day, seven days a week.

G4S started taking and making calls from 20 June for appointments from 1 July onwards.

Until 30 June, the bookings line number will remain 08432 241 888.

From 1 July, the bookings line number will be 0800 096 0211.

All bookings made with NSL for dates from 1 July onwards are being transferred to G4S and patients are being phoned to personally reassure them of this.

For further information about the new patient transport service in Kent and Medway, including alternatives for people who are not eligible for patient transport, please visit www.km-pts.co.uk

go to top